The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Open accessAbstract
Introduction Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy.Methods We conducted a prospective cohort study of patients with advanced NSCLC who were treated with nivolumab between January and December 2016. The association between clinical outcome and irAEs 2 to 6 weeks after commencement of nivolumab treatment was investigated. IrAEs were assessed by at least three independent medical professionals.Results A total of 43 patients were enrolled, including 19 patients with irAEs 2 weeks after commencement of nivolumab treatment. Common irAEs included rash, pyrexia, and diarrhea. Programmed cell death ligand 1-positive tumor cell expression was not significantly different between patients with and without irAEs. The objective response and disease control rates were higher in patients with irAEs than in those without irAEs (37% versus 17% and 74% versus 29% [p = 0.17 and p < 0.01], respectively]). Patients with irAEs were associated with a significantly longer median progression-free survival than those without (6.4 months [95% confidence interval: 2.5-not reached] versus 1.5 months [95% confidence interval: 1.2-2.3] [p = 0.01]). These findings were comparable to those for patients with and without irAEs 6 weeks after commencement of nivolumab treatment.Conclusions Early irAEs are associated with a better outcome after treatment with immunotherapy. We predicted responses to nivolumab by using early irAEs. Further research is needed to elucidate the mechanisms of these associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both ORR and DCR were higher in patients who experienced IRAEs at ≤2 weeks and ≤ 6 weeks compared to those who did not experience them.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991
Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,505
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 664
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · cited 2×
“Recently, dermatological irAEs and immunotherapy-related thyroid dysfunction have been associated with a clinical benefit to ICIs in patients with NSCLC.(16,17) However, no prospective clinical trials have been conducted and little is known regarding the association between irAEs and the outcome of patients with NSCLC…”
BackgroundDowney, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Rusch, V. W., Crowley, J. J., Giroux, D. J., Goldstraw, P. G., Im, J.-G., Tsuboi, M., Tsuchiya, R., & Vansteenkiste, J. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31807ec803 · Cited by 513
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Villadolid, J. J., & Amin, A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 417
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293
Chen, T. W., Razak, A. R. A., Bedard, P. L., Siu, L. L., & Hansen, A. R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv182 · Cited by 247
Reassessing target antigens for adoptive T-cell therapy
Hinrichs, C. S., & Restifo, N. P. (2013) · Nature Biotechnology · doi:10.1038/nbt.2725 · Cited by 216
Ali, O. H., Diem, S., Markert, E., Jochum, W., Kerl, K., French, L. E., Speiser, D. E., Früh, M., & Flatz, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231292 · Cited by 117
Nishio, M., Hida, T., Atagi, S., Sakai, H., Nakagawa, K., Takahashi, T., Nogami, N., Saka, H., Takenoyama, M., Maemondo, M., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000108 · Cited by 69
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 64
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 550
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 486
Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
Hussaini, S. M. Q., Chehade, R., Boldt, G., Raphael, J., Blanchette, P., Vareki, S. M., & Fernandes, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102134 · Cited by 412
Metadata
- Authors
- Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., Nagata, K., Nakagawa, A., Otsuka, K., Uehara, K., Imai, Y., Ishida, K., Fukuoka, J., & Tomii, K.
- Affiliations
- Kobe City Medical Center General Hospital (JP)
- Hyogo Medical University (JP)
- Nagasaki University Hospital (JP)
- Corresponding author
- Fujimoto, Daichi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 12
- Issue
- 12
- Pages
- 1798-1805
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2754877046
- Cited by
- 375
- References
- 26
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 29 · 2023: 29 · 2022: 44 · 2021: 68 · 2020: 79 · 2019: 67 · 2018: 22 · 2017: 2
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- immune-related adverse events, nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, progression-free survival, PD-L1 expression, rash, fever, diarrhea, objective response rate
- MeSH terms
- Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Prospective Studies, Cohort Studies, Treatment Outcome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
